Global Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Insights, Forecast to 2029

Publication ID:

PB503235887

Publication Date:

March 27, 2023

Pages:

126

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Radiopharmaceuticals in Nuclear Medicine market is projected to grow from US$ 5214.7 million in 2023 to US$ 6988.2 million by 2029, at a Compound Annual Growth Rate (CAGR) of 5.0% during the forecast period.
The US & Canada market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key manufacturers of Radiopharmaceuticals in Nuclear Medicine include Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group and Isotec, Inc. (Sigma-Aldrich), etc. In 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes:
This report presents an overview of global market for Radiopharmaceuticals in Nuclear Medicine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Radiopharmaceuticals in Nuclear Medicine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Radiopharmaceuticals in Nuclear Medicine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Radiopharmaceuticals in Nuclear Medicine sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Radiopharmaceuticals in Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Radiopharmaceuticals in Nuclear Medicine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group and Isotec, Inc. (Sigma-Aldrich), etc.
By Company
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Segment by Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Segment by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Radiopharmaceuticals in Nuclear Medicine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radiopharmaceuticals in Nuclear Medicine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Study Coverage
1.1 Radiopharmaceuticals in Nuclear Medicine Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Diagnostic Radiopharmaceuticals
1.2.3 Therapy Radiopharmaceuticals
1.2.4 Enriched Stable Isotopes
1.3 麻豆原创 by Application
1.3.1 Global Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Diagnostic Application
1.3.3 Therapeutic Application
1.3.4 Research
1.3.5 Pharmaceutical
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts 2018-2029
2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region
2.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2018-2023)
2.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2024-2029)
2.2.4 Global Radiopharmaceuticals in Nuclear Medicine Revenue 麻豆原创 Share by Region (2018-2029)
2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts 2018-2029
2.4 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
2.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2018-2023)
2.4.3 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2024-2029)
2.4.4 Global Radiopharmaceuticals in Nuclear Medicine Sales 麻豆原创 Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers
3.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2018-2023)
3.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales 麻豆原创 Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Radiopharmaceuticals in Nuclear Medicine in 2022
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (2018-2023)
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue 麻豆原创 Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Radiopharmaceuticals in Nuclear Medicine Revenue in 2022
3.3 Global Key Players of Radiopharmaceuticals in Nuclear Medicine, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Product Offered and Application
3.8 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type
4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales by Type (2018-2023)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Sales by Type (2024-2029)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Revenue by Type (2018-2023)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Revenue by Type (2024-2029)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Type
4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2018-2023)
4.3.2 Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Type (2024-2029)
5 麻豆原创 Size by Application
5.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application
5.1.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales by Application (2018-2023)
5.1.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Sales by Application (2024-2029)
5.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Revenue by Application (2018-2023)
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Revenue by Application (2024-2029)
5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Application
5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2018-2023)
5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Type
6.1.1 US & Canada Radiopharmaceuticals in Nuclear Medicine Sales by Type (2018-2029)
6.1.2 US & Canada Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2018-2029)
6.2 US & Canada Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Application
6.2.1 US & Canada Radiopharmaceuticals in Nuclear Medicine Sales by Application (2018-2029)
6.2.2 US & Canada Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2018-2029)
6.3 US & Canada Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Country
6.3.1 US & Canada Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Radiopharmaceuticals in Nuclear Medicine Sales by Country (2018-2029)
6.3.3 US & Canada Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Type
7.1.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Type (2018-2029)
7.1.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2018-2029)
7.2 Europe Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Application
7.2.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Application (2018-2029)
7.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2018-2029)
7.3 Europe Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Country
7.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2018-2029)
7.3.3 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size
8.1.1 China Radiopharmaceuticals in Nuclear Medicine Sales (2018-2029)
8.1.2 China Radiopharmaceuticals in Nuclear Medicine Revenue (2018-2029)
8.2 China Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Application
8.2.1 China Radiopharmaceuticals in Nuclear Medicine Sales by Application (2018-2029)
8.2.2 China Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Type
9.1.1 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Type (2018-2029)
9.1.2 Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2018-2029)
9.2 Asia Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Application
9.2.1 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Application (2018-2029)
9.2.2 Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2018-2029)
9.3 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Region
9.3.1 Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2018-2029)
9.3.3 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country
10.3.1 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bracco Imaging S.P.A.
11.1.1 Bracco Imaging S.P.A. Company Information
11.1.2 Bracco Imaging S.P.A. Overview
11.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bracco Imaging S.P.A. Recent Developments
11.2 Cambridge Isotope Laboratories, Inc.
11.2.1 Cambridge Isotope Laboratories, Inc. Company Information
11.2.2 Cambridge Isotope Laboratories, Inc. Overview
11.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Cambridge Isotope Laboratories, Inc. Recent Developments
11.3 Cardinal Health, Inc.
11.3.1 Cardinal Health, Inc. Company Information
11.3.2 Cardinal Health, Inc. Overview
11.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Cardinal Health, Inc. Recent Developments
11.4 Covidien, Plc
11.4.1 Covidien, Plc Company Information
11.4.2 Covidien, Plc Overview
11.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Covidien, Plc Recent Developments
11.5 Eczacibasi-Monrol
11.5.1 Eczacibasi-Monrol Company Information
11.5.2 Eczacibasi-Monrol Overview
11.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Eczacibasi-Monrol Recent Developments
11.6 Fujifilm Holdings Corporation
11.6.1 Fujifilm Holdings Corporation Company Information
11.6.2 Fujifilm Holdings Corporation Overview
11.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Fujifilm Holdings Corporation Recent Developments
11.7 GE Healthcare (Subsidiary Of General Electric Company)
11.7.1 GE Healthcare (Subsidiary Of General Electric Company) Company Information
11.7.2 GE Healthcare (Subsidiary Of General Electric Company) Overview
11.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments
11.8 IBA Group
11.8.1 IBA Group Company Information
11.8.2 IBA Group Overview
11.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 IBA Group Recent Developments
11.9 Isotec, Inc. (Sigma-Aldrich)
11.9.1 Isotec, Inc. (Sigma-Aldrich) Company Information
11.9.2 Isotec, Inc. (Sigma-Aldrich) Overview
11.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments
11.10 Lantheus Medical Imaging, Inc.
11.10.1 Lantheus Medical Imaging, Inc. Company Information
11.10.2 Lantheus Medical Imaging, Inc. Overview
11.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Lantheus Medical Imaging, Inc. Recent Developments
11.11 Nordion, Inc.
11.11.1 Nordion, Inc. Company Information
11.11.2 Nordion, Inc. Overview
11.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Nordion, Inc. Recent Developments
11.12 Ntp Radioisotopes (Pty), Ltd.
11.12.1 Ntp Radioisotopes (Pty), Ltd. Company Information
11.12.2 Ntp Radioisotopes (Pty), Ltd. Overview
11.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments
11.13 Siemens Healthcare (Subsidiary Of Siemens AG)
11.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Company Information
11.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Overview
11.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments
11.14 Taiyo Nippon Sanso Corporation
11.14.1 Taiyo Nippon Sanso Corporation Company Information
11.14.2 Taiyo Nippon Sanso Corporation Overview
11.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.14.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Taiyo Nippon Sanso Corporation Recent Developments
11.15 Urenco Limited
11.15.1 Urenco Limited Company Information
11.15.2 Urenco Limited Overview
11.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.15.4 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Urenco Limited Recent Developments
11.16 Rotem Industries, Ltd., Inc.
11.16.1 Rotem Industries, Ltd., Inc. Company Information
11.16.2 Rotem Industries, Ltd., Inc. Overview
11.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.16.4 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Rotem Industries, Ltd., Inc. Recent Developments
11.17 Australian Nuclear Association And Technology Organization (ANSTO)
11.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Company Information
11.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Overview
11.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments
11.18 Board of Radiation And Isotope Technology (BRIT)
11.18.1 Board of Radiation And Isotope Technology (BRIT) Company Information
11.18.2 Board of Radiation And Isotope Technology (BRIT) Overview
11.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.18.4 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments
11.19 Institute of Atomic Energy Polatom Radioisotope Centre
11.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Company Information
11.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Overview
11.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments
11.20 Institute of Isotopes Co., Ltd.
11.20.1 Institute of Isotopes Co., Ltd. Company Information
11.20.2 Institute of Isotopes Co., Ltd. Overview
11.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.20.4 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Institute of Isotopes Co., Ltd. Recent Developments
11.21 Institute Of Radioelement (IRE)
11.21.1 Institute Of Radioelement (IRE) Company Information
11.21.2 Institute Of Radioelement (IRE) Overview
11.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2018-2023)
11.21.4 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Institute Of Radioelement (IRE) Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
12.2 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
12.4 Radiopharmaceuticals in Nuclear Medicine Sales and 麻豆原创ing
12.4.1 Radiopharmaceuticals in Nuclear Medicine Sales Channels
12.4.2 Radiopharmaceuticals in Nuclear Medicine Distributors
12.5 Radiopharmaceuticals in Nuclear Medicine Customers
13 麻豆原创 Dynamics
13.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
13.2 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Drivers
13.3 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Challenges
13.4 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Restraints
14 Key Findings in The Global Radiopharmaceuticals in Nuclear Medicine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

Companies Mentioned:

Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.